dota-nhs-ester

DOTA-NHS-ester is a linker for affibody molecules with applications in small animal PET, SPECT, and CT. It can be used to label radiotherapeutic agents or imaging probes for tumor detection.

DOTA-NHS-ester (hexafluorophosphate TFA) is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative utilized for tumor pre-targeting. It is applicable in the conjugation of peptides and radionuclides.

DOTA-NHS-ester (TFA) serves as a linker for affibody molecules, and it is applicable in small animal imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and CT scans. It can also be used to label radiopharmaceuticals or imaging probes for tumor detection.

DOTA-tris(tBu)ester NHS ester, a derivative of DOTA, serves for the labeling of peptides and antibodies.

Rosopatamab is a humanized monoclonal antibody targeting prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer. It can be conjugated with radiolabeled isotopes (e.g., 177Lu) via DOTA-NHS ester to form radiopharmaceuticals for targeted therapy. In preclinical studies, 177Lu-DOTA-Rosopatamab combined with the DNA-PK inhibitor Peposertib achieved a 75% complete response rate in prostate cancer mouse models.

DOTAM-NHS-ester is a bifunctional chelator (Bifunctional Chelator; BFC) and a macrocyclic DOTA derivative utilized in tumor pre-targeting. It is suitable for conjugation with peptides and radionuclides.